CSHP Advocates for Pharmacy Professionals in CT

CSHP represents you and your interests as a pharmacy professional. We work to create the best possible work environment for all. During the legislative session, our lobbyist and legislative committee track activity and use a service called Bill Book.
Click to read the latest Bill Book: March 18
2016 Bill Book Archive:  March 12   March 4

CSHP has become a member of Patient Access to Pharmacists’ Care Coalition (PAPCC), a coalition spearheaded by ASHP that is working to obtain nationwide provider status for pharmacists in the Medicare program. For information about PAPCC, go to http://pharmacistscare.org   To see who are current members of the coalition (more being added each day), go to http://pharmacistscare.org/about-papcc/

Resolve to Build Support for Provider Status in 2016  

The Pharmacy and Medically Underserved Areas Enhancement Act received strong support in 2015, but there's still much work to do before this provider status legislation can be enacted into law. As the second half of the 114th Congress begins, invite your representative and senators to visit your practice site for an up-close look at the ways you care for patients. Use ASHP's toolkit for tips on how to extend an invitation and plan for the site visit. (source: ASHP NewsLink 12.22.15)

You can make a difference. Please read the May 2015 update, review the attached documents and contact your legislator to share the details of how Medication Therapy Management (MTM) can save money for the CT budget. Our goal is to have this language inserted into the final appropriations bill.

See the link below for members of the Appropriations Committee.

Map, Districts, Representatives with contact information



State Representatives and Senators

A resource to locate and contact your local CT representatives, visit http://www.cga.ct.gov/maps/townlist.asp

posted October 8, 2015
Connecticut House Speaker Rules Out Special Session On Hospital Medicaid Cuts.
The Connecticut Post (10/2) reports that Connecticut House Speaker Brendan Sharkey (D) “on Thursday ruled out the possibility of a special session to reconsider the governor’s cuts to state hospitals.” The article notes Gov. Dannel P. Malloy’s (D) cuts to the current year’s budget would reduce Medicaid funding for state hospitals by about $63 million. “We are not in crisis and a special session is not necessary and would be counter-productive,” Sharkey said, adding, “I still plan to work with the leadership of the Senate to identify cuts that will help restore funding to local hospitals.”
(source: ASHP Daily Briefing)

posted October 15, 2015

Only 1 CT legislator has signed on so we urge you to contact your representatives.

Provider Status Legislation Reaches Milestone   http://cqrcengage.com/ashp/app/write-a-letter?0&engagementId=76964
A majority of the members of the House of Representatives now support provider status legislation! While this is an important milestone, it's critical that we continue to add cosponsors and reaffirm the commitment of those legislators who are already listed as supporters. Send an e-mail to your members of Congress asking them to support provider status. Personalize the e-mail provided with examples from your practice that demonstrate the value you bring to the healthcare team. (source: ASHP)

Posted August 20, 2015


Please reach out to your members of Congress or send a letter supporting the Provider status bill if you haven’t already done so. 


At this time only 33 more cosponsors are needed in the House to get to the “magic” number of 218, which means a majority of representatives would likely vote for the bill.  Currently in Connecticut there is only 1 Co-Sponsor

To find out who represents you in CT government and an interactive map to help you find your legislator, see above.

Click on the "ASHP National Advocacy" page for informative tools to help you when you make contact.
CSHP Legislative and Advocacy Initiatives

Legislative Committee Update: May 2015
With one month to go in the Connecticut legislative session, CSHP continues to monitor the many healthcare related bills that affect pharmacy practice, and specifically health systems pharmacy in Connecticut and in Congress. In Connecticut, bills that continue to be active that we are following include those involving the dispensing or administering of opioid antagonists (HB5782 & HB6856), the requirement of manufacturer information on generic prescription drug labels for MedWatch reporting (SB28), health insurance coverage for off-label prescription drugs (SB418), in addition to many other bills that look to be dying in committee or not making it to a final floor vote.

A bill of specific interest that CSHP is advocating for, along with the other pharmacy organizations and pharmacy schools in the State, continues to be Medicaid reimbursement for pharmacist medication management services. While this bill has not been raised in committee, it does have the interest of many legislators and may be added into the session-ending implementer bill. The interest of legislators continues to be the cost-saving aspects of pharmacist medication management provided to high-risk Medicaid patients. Click to read a document on this advocacy, which includes background information on the topic, and suggested legislative language for the implementer bill.

At this late point in the legislative session, we strongly urge you to talk with any of your House or Senate members that may be your representatives from where you live or where you work. All of them may play a role in the final implementer bill vote, but particularly those that are in the House or Senate leadership or the many members of the Appropriations Committee. CSHP has been working closely with the other pharmacy organizations and schools of pharmacy in a workgroup specifically organized to advocate for this bill in this legislative session. We have seen great interest from legislators, despite their initial hesitancy given the State’s deficit, however focusing on the health cost savings that can occur within ONE YEAR of implementation greatly peaks their interest in this proposal.

The state Medicaid reimbursement initiative is similar in many ways to the federal Medicare bills being debated now in Congress (H.R.592 & S.314). Click for an overview document.Currently, there are 131 House co-sponsors (none from Connecticut, although Rep. Courtney was a co-sponsor on last year’s version, and should be supportive), and there are 15 Senate co-sponsors (also none from Connecticut, Senator Blumenthal’s health liaison has been detailed on the bill, and we expect the Senator to visit a Connecticut pharmacy soon). Your outreach through emails, calls or visits with your Congressional member will have an important role in bringing them on as co-sponsors for these bills. The more co-sponsors the bills have, the more likely the bill will have an easier time passing through committees and coming to floor votes. It’s critical to remind the House and Senate members that this legislation is completely bi-partisan, as you’ll see that there is currently a virtual even distribution in party affiliations of co-sponsors – there is a strong desire to support bipartisan bills in Congress, especially those that can provide health cost savings and improve health outcomes.
March 16, 2015 CE Program Materials
"The Stars are Aligned for State and Federal Pharmacist Reimbursement:
Why You Are the Key to Success!"

Presentation slides which include links to websites that will allow people to access materials for both the state and federal legislation initiatives.
  • For the federal legislation: There is a link to the PAPCC website (slide #22) that has great materials for the federal bill, and a link to sending your member of Congress an email (slide #29).
  • For the state legislation: There is a link on how to find your state rep and senator, and members of the Human Services and Appropriations Committees (slide #30).

Additional Material
CSHP Legislative and Advocacy Initiatives


The Connecticut General Assembly has convened their legislative session with a relatively similar membership of Representatives and Senators from the previous session. The House (87-64) and Senate (21-15) will continue to have a Democratic majority; however the leadership of both chambers and many committees has changed. The list of leadership positions and committee members are attached to this report. Advocating for issues important to the pharmacy profession will be much more effective if you know your own Representative and Senator, particularly if they are members of important committees to many of our issues, i.e. the Public Health Committee, General Law Committee, and Human Services Committee. It is also important to note that the Department of Consumer Protection has a new Commissioner, Jonathan Harris, who has been an important advocate in previous pharmacy legislative issues such as collaborative practice, when he was Chair of the Public Health Committee.

With the beginning of the legislative session we have important information to announce. In recent months, CSHP has worked closely with other entities in the pharmacy and medical community to discuss legislation for reimbursement of pharmacist medication management services to Medicaid patients. We’re happy to state that this week legislative language was submitted and accepted into the Public Health Committee by Representative Theresa Conroy. Here is the current language for what is now considered a “concept bill”:

“The Department of Social Services shall pay credentialed pharmacists for Medication Therapy Management services for beneficiaries taking 3 or more chronic medications to improve medication safety and health outcomes.”

There will be a long way to go in this process, as we anticipate multiple variations to the language as it goes through various committees, a public hearing, and a fiscal analysis. CSHP will be part of a work group consisting of representatives from CPA, CT-ASCP, and the UConn and St. Joseph Schools of Pharmacy. This group will work collaboratively to shepherd the bill through the legislative process and provide leadership for their members to advocate for the bill. Achieving medication management reimbursement for Medicaid patients would be a landmark achievement for our profession, and a significant complement to the federal Medicare provider recognition initiative, which Joe Hill described at this year’s Catch the Wave Conference as ASHP’s major legislative goal. Strengthening our initiative is the timely release from the National Governors Association titled “The Expanding Role of Pharmacists in a Transformed Health Care System.” The document is attached to this report, and has also been submitted to the Public Health Committee and Governor Malloy, as evidence of the widely recognized importance of pharmacist medication management services to improve therapeutic outcomes and reduce health care costs.

CSHP will continue to update you on the progress of this legislative initiative and coordinate how you can become an important advocate to your legislator to make this law a reality.


The Connecticut General Assembly 2014 regular session ran from February 5th to May 7th. Since it was a short session this year, there were not opportunities for too many new legislative initiatives to be introduced. However, CSHP  monitorrf continuing legislative activity, including bills that may have been introduced previously and died in committees, and any potential amendments to bills that would affect pharmacy practice. We received bill tracking reports every week that screened the hundreds of bills which could impact our profession or health care at large.


Members had an opportunity to interact with legislators and their staff during Pharmacy Day at the Capitol, which is a yearly reception in the lobby of the Legislative Office Building, sponsored jointly by the state pharmacy organizations. 


In addition to monitoring legislative activity on the state and national level, CSHP also was involved in discussions with the Pharmacy Commission on a proposal to institute “tech-check-tech” (TCT) capabilities for interested hospitals. The UConn School of Pharmacy and CSHP sent a survey to all hospital pharmacies to assess various dispensing practices, the credentialing and use of technicians, and the desire to use TCT services at their institution. Collaborations with all interested parties (i.e. pharmacy organizations, hospitals, Pharmacy Commission, Drug Control) took place after analysis of the survey results. The survey results also will be released in the CSHP newsletter at a later date. Stay tuned for more details for this exciting initiative that will be one of Connecticut’s contributions to the continuing Pharmacy Practice Model Initiative (PPMI), ASHP’s commitment to improving institutional pharmacy practice.

May 2014 CSHP Legislative Session Outcomes

The 2014 legislative session wrapped up in May with the usual flurry of last minute votes and the annual “implementor” bill that typically combines over 100 unrelated bills that hadn’t passed previously – it passed at 11:47pm, with 13 minutes in the session to spare! With the needless confusion this process creates, it makes it quite challenging to even find bills of specific interest to the general pharmacy and health-systems pharmacy community. With the assistance of our CSHP lobbyist, Fred Knous, and his bill tracking operation, we were able to comment on various bills throughout the session and oversee language changes in some cases.


In addition to monitoring the legislative session, CSHP has taken the lead on initiating efforts to explore tech-check-tech (TCT) opportunities in Connecticut hospitals. A survey has gone out to all hospital pharmacy directors/managers on the use and training of their technicians, current technology used for dispensing operations in their facilities, and the desirability of TCT in their institution. In addition to the statewide survey, a compilation of current TCT practices in other states has been conducted to assess various methods of implementation and success rates. We will continue to be in discussion with various entities in the state regarding potential TCT implementation, including the Pharmacy Commission, Drug Control, the Connecticut Hospital Association and other pharmacy organizations. Updates in the newsletter will be provided on TCT status as it progresses.

Below is a summary of bills that passed in the Connecticut legislature that may be of interest in the pharmacy/medical world in which we practice:



This bill was actively monitored by CSHP and the CT Hospital Association (CHA). We thank Jan Kozakiewicz and Michael Rubino for their input on various iterations of the bill’s language as it went through the process. CSHP supported substitute language submitted by CHA and in the final version, much of the language was changed to our approval, however the final passed version may impact hospital pharmacy practice. The bill makes several changes to pharmacy law, here is a summary of the bill’s content:

  1. Sterile Compounding:
    a. The bill requires sterile compounding pharmacies to comply with USP 797, and maintain a policy and procedure manual that complies with USP standards, including among other things, sterilization methods and training.
    b. A “sterile compounding pharmacy” is a pharmacy, including any located in healthcare institution, or a nonresident pharmacy that dispenses or compounds sterile pharmaceuticals.
    c. The bill requires sterile compounding pharmacies to file an addendum to their pharmacy application with DCP before compounding sterile pharmaceuticals for use in the state. DCP, or the appropriate state oversight agency for nonresident pharmacies, must inspect the changes and DCP and the Pharmacy Commission must approve them before a pharmacy can begin compounding sterile pharmaceuticals.
    d. The bill allows a sterile compounding pharmacy to provide patient-specific sterile pharmaceuticals only to patients, physicians, osteopaths, podiatrists, dentists, veterinarians; an acute care or long-term care hospital; or a Department of Public Health (DPH) licensed health care facility.
    e. The bill requires sterile compounding pharmacies that provide compounded sterile products without a prescription or medical order to get a DCP manufacturing license and any required federal license or registration. A sterile compounding pharmacy may prepare and maintain on-site up to a 30-day supply of sterile pharmaceuticals. The 30 days start from the day compounding is completed, including third party analytical testing performed according to pharmacopeia standards.
    f. The bill requires sterile compounding pharmacies to notify DCP at least 10 days before remodeling or relocating a pharmacy clean room.
    g. The bill requires sterile compounding pharmacies, other than those in health care institutions, to give DCP a written report of any known violation or noncompliance with viable and nonviable environmental sampling testing, as defined by pharmacopeia standards, within one business day after discovery. A sterile compounding pharmacy within a health care facility must report the violation or noncompliance to DPH.
    h. The bill requires sterile compounding pharmacies to notify certain people when they recall sterile pharmaceuticals. By the end of the business day following the recall, they must notify (1) each patient or patient caregiver, the prescribing practitioner, and DCP when the pharmaceutical was dispensed as a patient-specific prescription or medical order and (2) each purchaser of the pharmaceutical, DCP, and the federal Food and Drug Administration (FDA) for pharmaceuticals that were not dispensed as a patient-specific prescription or medical order.
  2. Counterfeit Substances
    The bill prohibits anyone from knowingly purchasing for resale, selling, offering for sale, or delivering a counterfeit substance in any manner. Existing law already prohibits several actions related to counterfeit or misbranded drugs.
  3. Nonresident pharmacy
    The bill broadens the categories of nonresident pharmacies that must (1) register in Connecticut, (2) comply with pharmacy reporting requirements, and (3) provide patient contract information.
  4. Drug Manufacturers
    The bill requires pharmacies that dispense compounded drugs without a prescription or an individual medical order to register in Connecticut as drug manufacturers regardless of whether their principal place of business is located in the state.
  5. Dispense as Written Prescriptions
    a. The bill creates new requirements for prescribing practitioners and pharmacists when dispensing drugs that cannot be substituted for a generic version.
    b. For written prescriptions, the bill requires the prescribing practitioner to indicate on the prescription form that the product is “brand medically necessary” or “no substitution.” The bill specifies that no prescription form may default to these terms.
    c. For telephoned prescriptions, the bill requires the pharmacist to write the phrase “brand medically necessary” or “no substitution” on the prescription or enter it in the electronic prescription record. The pharmacist must also record on the prescription (1) the time the telephone prescription was received and (2) name of the person who ordered the prescription.
    d. For electronic prescriptions, the bill requires the prescribing practitioner to select the “dispense-as-written” code. The bill specifies that no electronic prescriptions may default to “brand medically necessary” or “no substitution.”
    e. For Medicaid recipients, current law requires prescribing practitioners to specify the basis on which the brand name drug and dosage form is medically necessary compared to a chemically equivalent generic drug substitution. The practitioner must write, in his or her handwriting, the phrase “BRAND MEDICALLY NECESSARY,” on the prescription form or on an electronically produced copy of the form. If the prescription was ordered by telephone or electronically and the form did not reproduce the practitioner's handwriting, then (1) a statement to that effect must still be on the form and (2) written certification in the practitioner's handwriting with the phrase “BRAND MEDICALLY NECESSARY” must be sent to the dispensing pharmacy within 10 days after the communication date. The phrase “BRAND MEDICALLY NECESSARY” must not be preprinted, stamped, or initialed on the form.


  • This bill bars certain health insurers that use prescription drug step therapy regimens from requiring their use for more than 60 days. Under the bill, “step therapy” is a protocol or program that establishes the specific sequence for prescribing drugs for a specified medical condition.
  • At the end of the step therapy period, the bill allows an insured's treating health care provider to determine that the step therapy regimen is clinically ineffective for the insured. At that point, the insurer must authorize dispensation of and coverage for the drug prescribed by the provider, if it is covered under the insurance policy or contract.
  • The bill requires insurers to establish and disclose to its providers a process by which they may request, at any time, an authorization to override any step therapy regimen.
  • This bill eliminates a requirement that a medical practitioner submit a hand-written prescription to a pharmacist stating “brand medically necessary” when he or she electronically submits a prescription for a medical assistance recipient specifying that there can be no substitution for the brand-name drug prescribed. The bill instead requires the prescriber to select the code on the certified electronic prescription that indicates a substitution is not allowed.
  • The bill also broadens the exception to the requirement that a pharmacist dispense a generically equivalent drug for a brand name one to a medical assistance recipient. Under the bill, a pharmacist must dispense the brand name drug when the prescriber specifies that there shall be no substitution for that drug. Currently, pharmacists may dispense such drugs to medical assistance recipients only if the phrase “brand medically necessary” is ordered.


  • This bill requires the public health (DPH) commissioner to develop and implement a plan to (1) reduce the incidence of chronic disease; (2) improve chronic disease care coordination in the state; (3) reduce the incidence and effects of chronic disease, and (4) improve outcomes for conditions associated with chronic disease.
  • The plan must address cardiovascular disease, cancer, lupus, stroke, chronic lung disease, diabetes, arthritis or another metabolic disease, and the effects of behavioral health disorders. It must be consistent with the (1) DPH's Healthy Connecticut 2020 health improvement plan and (2) state healthcare innovation plan developed under the State Innovation Model Initiative by the Centers for Medicare and Medicaid Services Innovation Center.
  • The bill requires the DPH commissioner, by January 15, 2015 and biennially thereafter, to report to the Public Health Committee
    1. description of the chronic diseases most likely to cause death or disability, the approximate number of people affected by them, and an assessment of each such disease's financial effect on the state, hospitals, and health care facilities;
    2. a description and assessment of programs and actions that DPH and health care providers have implemented to improve chronic disease care coordination and prevent disease;
    3. the source and amount of funding DPH receives to treat people with multiple chronic diseases and to treat or reduce the most prevalent chronic diseases in the state; 
    4. a description of care coordination between DPH and health care providers to prevent and treat chronic disease;
    5. recommendations on actions health care providers and people with chronic diseases can take to reduce the incidence of effects of these diseases. 


For more information on CSHP’s legislative initiatives,
please contact 
Tom Buckley, Legislative Chair

2013 Legislative Session Outcomes

The Connecticut General Assembly ended their legislative session on June 5th and CSHP was monitoring numerous bills throughout the session. Here is a recap of the status of the bills as of the end of this session (beginning with passed bills):

SB903: Increasing the Membership of the Commission of Pharmacy

Purpose: To increase the membership of the Commission of Pharmacy from six to seven members, and to specify that one of the pharmacist members be from an independent retail setting and another from a chain retail setting.

Status: PASSED and sent to Governor for signing

HB5747: Synchronizing Prescription Refills

Purpose: To require individual insurance policies to cover refills of prescription drugs made in accordance with a plan to synchronize refilling multiple prescriptions for certain insured persons.

Status: PASSED and sent to Governor for signing

HB6644: Various Revisions to the Public Health Statutes

Purpose: To make various changes to the public health statutes. Statutes affected include Biomedical Research Trust Fund, cancer screening services, long-term care facilities, definition of “institution” (added short-term hospital special hospice, hospice inpatient facility), institutional licensing fees, institutional inspections, etc.

Status: PASSED and signed by Governor

HB6389: Prescription Drug Monitoring

Purpose: To require health care practitioners to register for access to the electronic prescription drug monitoring program.

Status: PASSED both chambers

HB6545: Medicaid Drug Step Therapy

Purpose: To make changes in Medicaid prior authorization requirements to ensure that eligible recipients and prescribers are informed of prior authorization denials.

Status: DIED on Senate calendar, PASSED in House with Amendment A

HB6545: Medicaid Drug Step Therapy

Purpose: To make changes in Medicaid prior authorization requirements to ensure that eligible recipients and prescribers are informed of prior authorization denials.

Status: DIED on Senate calendar, PASSED in House with Amendment A

SB857: The Use of Step Therapy for and Off-Label Prescribing of Prescription Drugs

Purpose: To regulate the imposition of certain prescription drug utilization requirements on insureds.

Status: DIED on Senate calendar

SB955: Pharmacy Audits

Purpose: To regulate pharmacy audits conducted by pharmacy benefit managers and other entities

Status: DIED on Senate calendar

SB958: Electronic Funds Transfer Payments by Pharmacy Benefits Managers to Pharmacies

Purpose: To require pharmacy benefit managers to pay claims, upon written request by a pharmacy, to such pharmacy by electronic funds transfer

Status: DIED on House calendar

HB5347: Prescription Drug Labels

Purpose: To lower the incidence of drug overdoses

Status: DIED on House calendar

HB5906: Prescriptions for Controlled Substances and Use of the Connecticut Prescription Monitoring and Reporting System

Purpose: To ensure health care practitioners are aware of patients’ histories of controlled drug use prior to prescribing controlled substances.

Status: DIED on House calendar

HB6320: Health Insurance Coverage of Orally and Intravenously Administered Medications

Purpose: To require health insurance that provides coverage for intravenously administered medications for the treatment or palliation or therapeutic intervention for the prevention of disabling or life-threatening chronic diseases to provide coverage for orally administered medications for such treatment, palliation or therapeutic intervention on a basis no less favorable than intravenously administered medications.

Status: DIED on House calendar

HB6439: The Disposal and Collection of Unused Medication

Purpose: To encourage the disposal of unwanted medication.

Status: DIED on House calendar


Legislative News from Congress (July 2013)

  • It is in health care providers’ best interest to make the healthcare reform initiatives authorized in the Affordable Care Act (ACA) work effectively and efficiently. Until the expected savings estimated to be forthcoming in the next decade from that reorganization federal funding for programs other than ACA programs will continue to face reductions. A case in point is the Prevention and Public Health Fund. Established in the ACA to provide supplemental funds for new program development and current program enhancements, the Fund is being used by the Administration as funding support for many programs for which there are funds authorized but not appropriated within the ACA. Of the $1.5 billion to be authorized to be appropriated for FY14 nearly half will be used to support and sustain existing programs within the Centers for Disease Control and Prevention. Of greater concern are the Administration’s cuts to existing programs recommended in the FY14 budget recommendation to support ACA implementation efforts. If Congress does not appropriate sufficient funds the Administration can be expected to maximize the use of transfer authority given to the Secretary of HHS to ensure that ACA programs are implemented…even at the cost of current, non-ACA programs. So, it is imperative that programs are implemented as quickly as possible. The estimated billions in savings are need to sustain traditionally federally funded programs.
  • New patient safety resource: Nearly 20% of Medicare beneficiaries discharged from the hospital are readmitted within 30 days. The number one cause of that readmission…an adverse drug event. The Agency for Healthcare Research and Quality (AHRQ) has released a new patient safety primer outlining the many problems that hospitals should pay attention to and resolve using the recommendations presented in “Adverse Events After Discharge.” One significant root cause for readmissions is poor communication among providers at transitions of care. One recommendation for reducing adverse medication events during transitions is for the hospital to have in place a formal medication reconciliation process.
  • FDA makes new MedWatch tool available: The Food and Drug Administration (FDA) now has a web-based tool to improve use of MedWatch adverse event reporting forms. MedWatchLearn allows health professionals, health professions students and consumers to practice completing the MedWatch form. The intent of this practice is to build greater confidence and increase the likelihood that the health professional, student or consumer will complete the form EVERYTIME they identify a problem with an FDA approved drug or medical device.
  • CDC to pilot HIV MTM with providers: The Tuesday, June 18, 2013 edition of the Federal Register includes a notice by the Centers for Disease Control and Prevention. The notice seeks public comment on the development of a new project between the CDC and Walgreens. The project would place community pharmacists with primary medical providers of HIV positive patients in ten pilot sites. The pharmacists will be responsible for providing medication therapy management related to HIV care. CDC is seeking comment on the MTM project, its approach to implementation, and the data set it will collect from the sites to aid in analysis of the project’s success and challenges.
  • ASHP comments on Draft Version of House Compounding Bill (6/24/13): Clear lines need to be defined between traditional compounding and compounding outsourcers, ASHP told the author of a draft compounding bill set to be considered by the House of Representatives. In a letter last week to Rep. Morgan Griffith (R-Va.), the Society noted that pharmacists who practice in hospital and health-system settings need to be assured that entities compound large scale, non-patient specific preparations are properly supervised to enable patients to receive safe medications. The draft legislation keeps traditional pharmacy compounding, including compounding within a hospital or health system, under the authority of state boards of pharmacy.


Winter 2013 Update

The CT legislative session has begun and will continue through early June. CSHP continues to monitor bills to be raised and discussed through a bill monitoring program, with weekly reports from our lobbyist, Fred Knous. If members wish to see a short synopsis of raised bills (and their fate through the legislative process), please contact Tom Buckley at thomas.e.buckley@uconn.edu.  Due to the very large volume of bills raised, we screen the bills that may affect our profession and follow those closely.

There was a lot of debate and federal level information about the compounding issue shared at the ASHP Midyear and also at CSHP's January CE meeting. It's likely there will be bills raised or at least discussions about this topic in our state legislature as well. We will determine how to respond, as appropriate, and may request input from our members as needed. Also on the federal level, ASHP indicated that they will make pharmacist provider recognition their number one legislative agenda in Congress this year. CSHP applauds this decision and has supported this initiative for over 10 years. Federal provider recognition would open the door for Medicare reimbursement for pharmacist medication management services, and may persuade Medicaid and commercial payers to consider this reimbursement option as well. CSHP will actively work toward opportunities in this area.

Finally, CSHP has begun discussions with the CT Pharmacy Commission on considering "tech-check-tech" authorization utilizing bar code technology. Multiple hospital pharmacy directors have expressed the desire to pursue this change in status as a PPMI initiative. We will continue to update the membership as activity occurs.


Again, if you have specific expertise and/or experience relative to the issues we may address, please contact Tom Buckley or the CSHP office. We urge you to assist CSHP in advocating for our profession and your professional future.